Applied Genetic Technologies (AGTC) – Management Comments
-
Applied Genetic Technologies (AGTC) Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene
-
Applied Genetic Technologies (AGTC) Announces Positive 12-Month Data from Highest Dose Groups in Ongoing XLRP Phase 1/2 Clinical Trial
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to AGTC Stock Lookup